Statute Details
- Title: Medicines (Clinical Trials) Regulations 2016
- Act Code: MA1975-S335-2016
- Type: Subsidiary legislation (SL)
- Enacting Act: Medicines Act (Cap. 176)
- Enacting power: Section 18 of the Medicines Act
- Commencement: 1 November 2016
- Status: Current version (as at 27 Mar 2026)
- Parts: Part 1 (General); Part 2 (Clinical trials of medicinal products); Part 3 (Miscellaneous); Part 4 (Application to pending clinical trials)
- Key provisions (from the extract): Definitions (reg. 2); Scope (reg. 3); Clinical trial certificates (regs. 7–9); Amendments (reg. 10); Serious breaches & urgent safety measures (reg. 11); Consent and information duties (regs. 16–20); Safety duties (regs. 21–22); Records and vigilance (regs. 23–25); Labelling (reg. 26); Offences (reg. 28)
- Schedules: First Schedule (Principles of good clinical practice); Second Schedule (Labelling requirements)
- Related legislation: Medicines Act; Human Biomedical Research Act 2015; Healthcare Services Act 2020; Medical Registration Act 1997; Dental Registration Act 1999
What Is This Legislation About?
The Medicines (Clinical Trials) Regulations 2016 (“MCTR Regulations”) set out the regulatory framework for running clinical trials of medicinal products in Singapore. In plain terms, they require sponsors and investigators to obtain authorisation (via clinical trial certificates), follow approved protocols, protect trial subjects, and report safety information to the Health Sciences Authority (HSA). The Regulations are designed to ensure that clinical trials are conducted ethically and safely, while also enabling regulatory oversight of investigational medicinal products.
The Regulations focus on “clinical trials of medicinal products” that are not observational trials. They sit under the Medicines Act and complement broader research governance instruments in Singapore. Practitioners should read the MCTR Regulations alongside the Human Biomedical Research Act 2015 (where applicable), and the Healthcare Services Act 2020 (particularly for licensing and premises/conveyance concepts used in definitions).
Overall, the MCTR Regulations operationalise a risk-based compliance model: before a trial begins, the sponsor must obtain a clinical trial certificate; during the trial, the sponsor and investigators must comply with good clinical practice, consent requirements, safety reporting, and labelling rules; and after or during the trial, records and notifications must be maintained and submitted to HSA.
What Are the Key Provisions?
1. Definitions and scope (regs. 2–3)
The Regulations begin with definitions that are crucial for determining whether a study is regulated as a “clinical trial” of a medicinal product. The extract shows definitions for “adverse event”, “adverse drug reaction”, “investigational medicinal product”, “auxiliary medicinal product”, “institutional review board”, and “clinical trial in an emergency situation”. These definitions drive the application of duties on safety reporting, consent, and labelling.
Regulation 3 sets the scope. Based on the extract, the Regulations apply to clinical trials of medicinal products that are not observational trials. This matters because observational studies may be governed by different rules and may not require the same clinical trial certificate process.
2. Clinical trial certificates and regulatory submissions (regs. 7–12)
A central compliance requirement is the clinical trial certificate. Regulation 7 provides that a clinical trial certificate is required. Regulation 8 addresses how to apply for the certificate, and regulation 9 sets out the conditions that attach to the certificate. Practically, the certificate functions as the regulatory “permission slip” and also as the benchmark against which conduct of the trial is measured.
Regulation 10 addresses amendments and substantial amendments to a clinical trial. This is important for sponsors because protocol changes are common as trials progress. The Regulations distinguish between types of amendments and require appropriate regulatory handling—typically meaning that certain changes cannot be implemented without approval or notification, depending on their nature and impact.
Regulation 11 requires notification of serious breaches and urgent safety measures. This is a key enforcement lever: if the trial deviates from required standards or if urgent actions are taken to protect subjects, HSA must be informed promptly. Regulation 12 requires notification of the status of the clinical trial, ensuring that regulators have visibility on whether trials are ongoing, suspended, terminated, or completed.
3. Conduct of trials: good clinical practice and certificate compliance (regs. 13–15)
The Regulations require that clinical trials be conducted in accordance with good clinical practice (reg. 13) and in accordance with the clinical trial certificate (reg. 14). The First Schedule sets out principles of good clinical practice. For practitioners, this means that compliance is not limited to the protocol text; it also includes overarching ethical and scientific standards.
Regulation 15 deals with the place of clinical trial. This provision is relevant to operational compliance: trials must be conducted at appropriate sites, and the Regulations’ definitions incorporate concepts from the Healthcare Services Act 2020 (such as “approved permanent premises” and “approved conveyance”). This linkage signals that trial conduct is tied to licensed healthcare service infrastructure.
4. Consent and information duties (regs. 16–20)
A major part of the Regulations is devoted to informed consent and the information that must be provided to subjects. Regulation 16 covers consent of subjects in clinical trials generally. Regulation 17 addresses consent in emergency situations, where subjects may be unable to consent and it may not be feasible to obtain consents from legal representatives within the “window period”.
Regulation 18 sets general requirements as to consent, while regulation 19 imposes a duty to give full explanation and information. Regulation 20 prohibits coercion. These provisions are designed to ensure that consent is voluntary, informed, and properly documented, and that vulnerable circumstances (including emergencies) are handled with safeguards.
For lawyers advising sponsors or investigators, the practical implication is that consent processes must be robust enough to withstand regulatory scrutiny: the content of information, the timing, the decision-making capacity of subjects, and the documentation of consent must align with the Regulations and the approved protocol.
5. Safety duties: urgent safety measures, suspension, and termination (regs. 21–22)
Regulation 21 requires urgent safety measures where necessary to protect subjects. This interacts with reg. 11 (notification of urgent safety measures). Regulation 22 addresses suspension or termination of a clinical trial. Together, these provisions create a structured response to safety signals: when risks emerge, the sponsor and investigators must act quickly, and the trial may need to be paused or stopped.
From a compliance standpoint, these duties require clear internal escalation procedures, safety monitoring arrangements, and decision-making authority. Counsel should ensure that sponsor-investigator agreements and trial governance documents allocate responsibilities for safety actions and reporting.
6. Records and vigilance reporting (regs. 23–25)
Regulation 23 requires a record of clinical trials. This is essential for auditability and for responding to regulatory queries. The Regulations also impose vigilance obligations: regulation 24 requires notifications of serious adverse events, and regulation 25 requires notifications of unexpected serious adverse drug reactions.
These reporting duties are central to pharmacovigilance. The definitions of “adverse event” and “adverse drug reaction” matter because they determine what must be reported and how causality and expectedness are assessed. Practitioners should ensure that safety data management systems can identify reportable events and meet notification timelines and content requirements.
7. Labelling requirements (reg. 26 and Second Schedule)
Regulation 26 governs labelling of investigational medicinal products and auxiliary medicinal products. The Second Schedule sets out labelling requirements. Correct labelling is not merely administrative: it supports safe use, traceability, and subject protection. It also reduces the risk of medication errors, especially where blinding or complex investigational regimens are involved.
8. Offences and enforcement (reg. 28) and information powers (reg. 27)
While the extract does not reproduce the text of regulation 28, the structure indicates that the Regulations contain offence provisions for non-compliance. Regulation 27 provides a power to obtain information, which supports regulatory investigations and compliance checks. In practice, these provisions enable HSA to demand documents, records, and explanations, and to take enforcement action where breaches occur.
9. Application to pending clinical trials (Part 4, reg. 29)
Part 4 addresses how the Regulations apply to pending clinical trials. Regulation 29 concerns revocation and pending clinical trials. This transitional mechanism is important for sponsors who had started trials under earlier regulatory arrangements or who needed to align with updated requirements.
How Is This Legislation Structured?
The MCTR Regulations are organised into four main parts:
Part 1 (General) contains the citation and commencement provision, definitions, and the scope of the Regulations.
Part 2 (Clinical trials of medicinal products) is the core regulatory framework. It is divided into:
(i) Division 1 (General): sponsors, principal investigators, and the investigator’s brochure (noting that the extract indicates some definitional elements were deleted/amended in later versions).
(ii) Division 2 (Regulatory submissions): clinical trial certificates, applications, conditions, amendments, and notifications of serious breaches/urgent safety measures and trial status.
(iii) Division 3 (General duties): good clinical practice, certificate compliance, trial site requirements, consent and information duties, coercion prohibition, safety measures, suspension/termination, and record-keeping.
(iv) Division 4 (Vigilance): serious adverse event and unexpected serious adverse drug reaction notifications.
(v) Division 5 (Labelling): labelling requirements for investigational and auxiliary medicinal products.
Part 3 (Miscellaneous) includes powers to obtain information and offences.
Part 4 (Application to pending clinical trials) provides transitional rules for trials already underway.
Who Does This Legislation Apply To?
The Regulations apply to parties involved in clinical trials of medicinal products in Singapore—most notably sponsors and investigators. Sponsors are responsible for regulatory submissions, obtaining and maintaining clinical trial certificates, ensuring compliance with conditions, and ensuring that safety reporting and record-keeping obligations are met. Investigators are responsible for conducting the trial in accordance with good clinical practice, the certificate, and the protocol, including consent processes and safety actions.
In addition, the Regulations’ definitions and consent framework indicate that institutional review boards play a role in reviewing protocols and consent methods (as reflected in the definition). Trial sites and healthcare service providers are also indirectly implicated through requirements on place of trial and the incorporation of Healthcare Services Act 2020 concepts.
Why Is This Legislation Important?
The MCTR Regulations are important because they translate ethical and scientific expectations into enforceable legal duties. For practitioners, the Regulations provide the compliance checklist that regulators will use to assess whether a trial is being run lawfully: certificate requirements, adherence to protocol and conditions, consent and information standards, safety monitoring and reporting, and labelling controls.
From a risk management perspective, the Regulations’ emphasis on serious breaches, urgent safety measures, and vigilance notifications means that sponsors must have operational systems for rapid identification, escalation, documentation, and reporting. Failure to comply can trigger regulatory action and potential offences under the Regulations.
Finally, the Regulations’ transitional provisions for pending trials and their linkage to other Singapore healthcare and research statutes mean that counsel must consider the broader regulatory ecosystem. Advice on clinical trial governance should therefore integrate: (i) the Medicines Act framework; (ii) the Human Biomedical Research Act 2015 where relevant; and (iii) the Healthcare Services Act 2020 for licensing and site-related concepts.
Related Legislation
- Medicines Act (Cap. 176)
- Human Biomedical Research Act 2015
- Healthcare Services Act 2020
- Medical Registration Act 1997
- Dental Registration Act 1999
Source Documents
This article provides an overview of the Medicines (Clinical Trials) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.